INTELLIPHARMACEUTICS INTL INC

As of August 31, 2023, INTELLIPHARMACEUTICS INTL INC carries a market capitalization of 2.61M, placing it among publicly traded companies globally. Its enterprise value stands at 4.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of August 31, 2023, INTELLIPHARMACEUTICS INTL INC has 33.09M shares outstanding.

These figures are as of August 31, 2023. The price-to-sales ratio is 2.89, and the price-to-book ratio stands at -0.20.

These figures are as of August 31, 2023. The EV/Sales ratio of 4.89 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.43M versus a market cap of 2.61M, with the gap driven by net debt and cash on the balance sheet.

As of August 31, 2023, INTELLIPHARMACEUTICS INTL INC maintains a current ratio of 0.06, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -17.23, indicating conservative leverage, while an interest coverage ratio of -10.28 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended August 31, 2023. Return on assets (ROA) is negative at -211.39, reflecting losses generated across the asset base. The company generates approximately 69,611.23 in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers.

As of the close on October 6, 2026, INTELLIPHARMACEUTICS INTL INC's stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.06.

Over the twelve months ended August 31, 2023, INTELLIPHARMACEUTICS INTL INC generated 904,946.00 in revenue and converted that into -3.17M in net income, yielding earnings per share of -0.09. EBITDA reached -2.41M, while operating income came in at -2.53M.

As of August 31, 2023, INTELLIPHARMACEUTICS INTL INC holds 400,102.00 in cash and equivalents against 2.22M in total debt, resulting in a net debt position of 1.78M. Total book value stands at -12.88M, with working capital of -13.58M providing operational flexibility.

INTELLIPHARMACEUTICS INTL INC produced 120,453.00 in operating cash flow over the twelve months ended August 31, 2023. After subtracting - - in capital expenditures, free cash flow totaled 120,453.00 - equivalent to 0.00 per share.

These figures cover the twelve months ended August 31, 2023. The operating margin of -279.57 and net profit margin of -350.72 provide insight into operational efficiency.

These figures cover the twelve months ended August 31, 2023. Free cash flow yield stands at 4.61, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt.

INTELLIPHARMACEUTICS INTL INC's most recent stock split took place on September 14, 2018 with a 10:1 split ratio.

As of August 31, 2023, INTELLIPHARMACEUTICS INTL INC has an Altman Z-Score of -111.11, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.